150 related articles for article (PubMed ID: 34147745)
1. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors.
Zhang H; Jing L; Liu M; Goto M; Lai F; Liu X; Sheng L; Yang Y; Yang Y; Li Y; Chen X; Lee KH; Xiao Z
Eur J Med Chem; 2021 Nov; 223():113634. PubMed ID: 34147745
[TBL] [Abstract][Full Text] [Related]
2. Selective VEGFR-2 inhibitors: Synthesis of pyridine derivatives, cytotoxicity and apoptosis induction profiling.
AbdelHaleem A; Mansour AO; AbdelKader M; Arafa RK
Bioorg Chem; 2020 Oct; 103():104222. PubMed ID: 32889383
[TBL] [Abstract][Full Text] [Related]
3. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
[TBL] [Abstract][Full Text] [Related]
4. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation.
Solum E; Hansen TV; Aesoy R; Herfindal L
Bioorg Med Chem; 2020 May; 28(10):115461. PubMed ID: 32245563
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities.
Xi JB; Fang YF; Frett B; Zhu ML; Zhu T; Kong YN; Guan FJ; Zhao Y; Zhang XW; Li HY; Ma ML; Hu W
Eur J Med Chem; 2017 Jan; 126():1083-1106. PubMed ID: 28039836
[TBL] [Abstract][Full Text] [Related]
7. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.
Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA
Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells.
Nafie MS; Amer AM; Mohamed AK; Tantawy ES
Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925
[TBL] [Abstract][Full Text] [Related]
9. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.
Zhang L; Cheng C; Li J; Wang L; Chumanevich AA; Porter DC; Mindich A; Gorbunova S; Roninson IB; Chen M; McInnes C
J Med Chem; 2022 Feb; 65(4):3420-3433. PubMed ID: 35114084
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.
Czodrowski P; Mallinger A; Wienke D; Esdar C; Pöschke O; Busch M; Rohdich F; Eccles SA; Ortiz-Ruiz MJ; Schneider R; Raynaud FI; Clarke PA; Musil D; Schwarz D; Dale T; Urbahns K; Blagg J; Schiemann K
J Med Chem; 2016 Oct; 59(20):9337-9349. PubMed ID: 27490956
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.
Yu M; Long Y; Yang Y; Li M; Teo T; Noll B; Philip S; Wang S
Eur J Med Chem; 2021 Jun; 218():113391. PubMed ID: 33823391
[TBL] [Abstract][Full Text] [Related]
12. Pyrido[2,3-b][1,5]benzoxazepin-5(6H)-one derivatives as CDK8 inhibitors.
Martínez-González S; García AB; Albarrán MI; Cebriá A; Amezquita-Alves A; García-Campos FJ; Martínez-Gago J; Martínez-Torrecuadrada J; Muñoz IG; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2020 Sep; 201():112443. PubMed ID: 32599324
[TBL] [Abstract][Full Text] [Related]
13. Optimization of 4,6-Disubstituted Pyrido[3,2-
Han Y; Zhang H; Wang S; Li B; Xing K; Shi Y; Cao H; Zhang J; Tong T; Zang J; Guan L; Gao X; Wang Y; Liu D; Huang M; Jing Y; Zhao L
J Med Chem; 2021 Sep; 64(18):13719-13735. PubMed ID: 34515481
[TBL] [Abstract][Full Text] [Related]
14. Discovery and SARs of 5-Chloro-
Wang Y; Chen X; Yan Y; Zhu X; Liu M; Liu X
J Med Chem; 2020 Mar; 63(6):3327-3347. PubMed ID: 32129996
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Pteridine-7(8
Dou D; Diao Y; Sha W; Su R; Tong L; Li W; Leng L; Xie L; Yu Z; Song H; Shen Z; Zhu L; Zhao Z; Xie H; Chen Z; Li H; Xu Y
J Med Chem; 2022 Feb; 65(3):2694-2709. PubMed ID: 35099969
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure.
Wang L; Zheng Y; Li D; Yang J; Lei L; Yan W; Zheng W; Tang M; Shi M; Zhang R; Cai X; Ni H; Ma X; Li N; Hong F; Ye H; Chen L
J Med Chem; 2021 Jun; 64(12):8127-8141. PubMed ID: 34081857
[TBL] [Abstract][Full Text] [Related]
18. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of indole-based [1,2,4]triazolo[4,3-a] pyridine derivatives as novel microtubule polymerization inhibitors.
Wu CJ; Wu JQ; Hu Y; Pu S; Lin Y; Zeng Z; Hu J; Chen WH
Eur J Med Chem; 2021 Nov; 223():113629. PubMed ID: 34175541
[TBL] [Abstract][Full Text] [Related]
20. Design and Synthesis of a 2-Amino-pyridine Derivative as a Potent CDK8 Inhibitor for Anti-colorectal Cancer Therapy.
Yan YY; Zhang XX; Xiao Y; Shen XB; Jian YJ; Wang YM; She ZH; Liu MM; Liu XH
J Med Chem; 2022 Oct; 65(19):13216-13239. PubMed ID: 36126227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]